BriaCell Therapeutics AI Stock Analysis
Want to see TSE:BCT full AI Analyst Report?
BriaCell Therapeutics (BCT) AI Stock Analysis
BriaCell Therapeutics
(TSX:BCT)
The score is primarily constrained by weak financial performance—no revenue, widening losses, and significant negative free cash flow that increases financing risk. Technicals provide some support (price above major moving averages with moderately positive RSI), but mixed momentum (negative MACD) limits conviction. Valuation is also a headwind because negative earnings make P/E less meaningful and there is no dividend support.
BriaCell Therapeutics (BCT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 42.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 7,300
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.67
- Revenue Growth
- ―
- EPS Growth
- 87.90%
- Country
- Canada
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BriaCell Therapeutics Business Overview & Revenue Model
Company Description
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently u...
BriaCell Therapeutics Financial Statement Overview
Summary
Financials reflect a clinical-stage, pre-revenue company with persistent and widening losses (TTM net loss ~-$34.7M) and heavy cash burn (TTM operating cash flow ~-$28.6M; free cash flow ~-$28.7M). The main offsetting strength is very low leverage (no meaningful debt) and positive equity in FY2025/TTM, but ongoing losses are consuming capital and imply continued dependence on external funding.
Income Statement
6Very NegativeBalance Sheet
38NegativeCash Flow
7Very Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -32.50K | -121.09K | -107.93K | 0 | 0 | 0 |
| EBITDA | -35.33M | -36.46M | -27.43M | -4.85M | -23.26M | -26.82M |
| Net Income | -34.71M | -35.42M | -26.63M | -4.79M | -20.30M | -26.84M |
Balance Sheet | ||||||
| Total Assets | 23.57M | 23.57M | 21.72M | 5.87M | 27.16M | 42.58M |
| Cash, Cash Equivalents and Short-Term Investments | 20.53M | 20.53M | 17.93M | 862.09K | 21.25M | 41.04M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.02M | 8.02M | 4.33M | 8.56M | 30.94M | 32.25M |
| Stockholders Equity | 16.39M | 16.39M | 17.94M | -2.38M | -3.78M | 10.33M |
Cash Flow | ||||||
| Free Cash Flow | -28.70M | -29.20M | -28.51M | -24.58M | -23.74M | -12.48M |
| Operating Cash Flow | -28.57M | -29.07M | -28.51M | -24.13M | -23.74M | -12.48M |
| Investing Cash Flow | -4.10M | -3.86M | -7.74M | -681.80K | 0 | 0 |
| Financing Cash Flow | 31.69M | 32.28M | 46.00M | 4.42M | 3.95M | -3.74M |
BriaCell Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BCT, the sentiment is Negative. The current price of 4.89 is above the 20-day moving average (MA) of 4.82, below the 50-day MA of 5.21, and below the 200-day MA of 5.22, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 48.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BCT.
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics disclosed 50 risk factors in its most recent earnings report. BriaCell Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBriaCell Therapeutics Peers Comparison
Overall Rating
TSE:MBX52Neutral- TSE:BCT45Neutral
TSE:DOSE39Underperform
TSE:RVX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:MBX | 52Neutral | CAD 40.41M | -8.36 | -18.83% | ― | -27.13% | -1752.63% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:BCT | 45Neutral | CAD 42.79M | -0.37 | -170.70% | ― | ― | 87.90% |
| TSE:DOSE | 39Underperform | CAD 13.78M | -4.25 | 42.51% | ― | -19.31% | 34.45% |
| TSE:RVX | 38Underperform | CAD 25.82M | -1.52 | 10.92% | ― | ― | 15.04% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BCT | BriaCell Therapeutics | 4.89 | -6.51 | -57.11% | |
| TSE:DOSE | Rapid Dose Therapeutics Corp | 0.10 | -0.06 | -37.50% | |
| TSE:MBX | Microbix Biosystms | 0.29 | 0.04 | 18.00% | |
| TSE:RVX | Resverlogix Corp. | 0.07 | -0.03 | -25.00% | |
| TSE:GSD | Devonian Health Group, Inc. | 6.30 | -5.40 | -46.15% | |
| TSE:TTI | Thiogenesis Therapeutics Corp | 0.64 | -0.06 | -8.57% |
BriaCell Therapeutics Corporate Events
BriaCell Reports Broad Preclinical Immunotherapy Activity at SITC
PositiveBriaCell reported preclinical data indicating Bria-OTS+ activated innate and adaptive immunity, enhanced cancer-cell killing after priming and boosting, and retained cytotoxic activity through repeated tumor challenges across breast, prostate and oth...
BriaCell and BriaPro Present Preclinical Immunotherapy Data
PositiveBriaCell and BriaPro announced four preclinical presentations at the Society for Immunotherapy of Cancer’s 2026 annual meeting. The research covered Bria-OTS+ and BriaPro programs including BP-80, TILsRx-001, and engineered CD80 variants, highlightin...
BriaCell Highlights New Immune Biomarker Data in Metastatic Breast Cancer at ESMO 2026
PositiveBriaCell Therapeutics reported new clinical biomarker data at the ESMO 2026 Congress from a pooled analysis of 111 heavily pretreated metastatic breast cancer patients treated with immune checkpoint inhibitors, some in combination with its Bria-IMT r...
BriaCell Advances Off-the-Shelf Personalized Melanoma Vaccine Toward Clinic
PositiveBriaCell Therapeutics has advanced its personalized melanoma immunotherapy vaccine candidate, Bria-MEL+, achieving a key genetic engineering milestone that moves the program closer to clinical development. Bria-MEL+ is designed as a whole-cell, off-t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026